Medical News

RSS

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

17 May 2010

Communication Intelligence first-quarter total revenue decreases to $207,000

Communication Intelligence Corporation, a leading supplier of electronic signature solutions for business process automation in the financial industry and the recognized leader in biometric signature verification, announced today its financial results for the first quarter ended March 31, 2010.

17 May 2010

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption.

17 May 2010

TriReme Medical receives FDA expanded clearance for GliderXtreme PTA balloon catheter

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its GliderXtreme™ PTA balloon catheter. GliderXtreme™ is now approved for the percutaneous transluminal treatment of lesions in the peripheral vasculature in balloon diameters from 2.0 – 5.0mm and in balloon lengths up to 200mm.

17 May 2010

FDA approves ROXRO PHARMA's SPRIX Nasal Spray

ROXRO PHARMA, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPRIX™ (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

17 May 2010

Cortex first-quarter net income increases to $0.08 per share

Cortex Pharmaceuticals, Inc. reported net income of approximately $5,596,000, or $0.08 per share for the quarter ended March 31, 2010 compared with a net loss of $3,168,000, or $0.07 per share for the corresponding prior year period, with the difference reflecting revenues from the Company's March 2010 transaction with Biovail Laboratories International SRL (Biovail).

17 May 2010

Hemispherx Biopharma to conduct study of Ampligen antiviral in China

As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.

17 May 2010

DARA BioSciences commences $10M underwritten public offering

DARA BioSciences, Inc. announced today that it has commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. The company intends to grant the underwriter in the offering an option to purchase up to $1.5 million of additional units to cover any over-allotments.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

Inovio Biomedical changes corporate name to Inovio Pharmaceuticals

Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics, Inc. today announced that Halozyme and Baxter have confirmed the presence of small flake-like glass particles in a limited number of vials of HYLENEX® (hyaluronidase human injection) product at the Baxter manufacturing facility. Earlier today, Halozyme notified the U.S. Food and Drug Administration that it is voluntarily recalling affected lots of 150U HYLENEX product from distribution.

17 May 2010

Providence Equity Partners to acquire Virtual Radiologic for $17.25 per share

Virtual Radiologic Corporation, a national radiology practice and a leader in the development of radiologist workflow technology, and Providence Equity Partners, a leading global private equity firm that manages over $22 billion in equity capital, today announced that they have entered into a definitive agreement under which Providence will acquire all of the outstanding common stock of vRad for $17.25 per share in cash.

17 May 2010

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.

17 May 2010

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Neovasc Inc., today announced financial results for the three months ended March 31, 2009.

17 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

Aeterna Zentaris' AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

17 May 2010

LLS's School & Youth Programs raise $1M to help fight against childhood cancer

Participants in The Leukemia & Lymphoma Society's Greater Los Angeles Chapter School & Youth(SM) Programs raised an unprecedented $1 million this spring, in a campaign that gives kids a chance to help in the fight against blood cancers.

17 May 2010

Tiens Biotech first-quarter revenues decrease to $11.4 million

Tiens Biotech Group (USA), Inc.,, today announced financial results for the first quarter ended March 31, 2010.

17 May 2010

Freescale Semiconductor receives ZigBee Certification for wireless health and wellness solutions

Freescale Semiconductor today announced it has received ZigBee Certified product status for its ZigBee Health Care wireless health and wellness processing platforms. The ZigBee Certified products status is awarded to products that have been tested and met criteria for interoperability that enable wireless devices to securely and reliably monitor and manage noncritical, low-acuity health care services.

17 May 2010